(S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide | 171856-35-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide
• 英文别名: (s)-n-Benzyl-n-methyl-2-phenylglycinamide；(2S)-2-amino-N-benzyl-N-methyl-2-phenylacetamide
• CAS: 171856-35-2
• 化学式: C₁₆H₁₈N₂O
• 分子量: 254.332
• InChiKey: OJPPLAWORTYMLZ-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide 在 盐酸 、 WSCD*HCl 、 1-羟基苯并三唑 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.25h， 生成
  参考文献：
  名称：

  Caliendo; Greco; Grieco, Il Farmaco, 1996, vol. 51, # 3, p. 197 - 201

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(叔丁氧羰基)-L-2-苯甘氨酸 在 盐酸 、 WSCD*HCl 、 1-羟基苯并三唑 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.25h， 生成 (S)-2-amino-N-benzyl-N-methyl-2-phenyl-acetamide
  参考文献：
  名称：

  Caliendo; Greco; Grieco, Il Farmaco, 1996, vol. 51, # 3, p. 197 - 201

  摘要：

  DOI：

文献信息

• Triamide-substituted heterobicyclic compounds
  申请人：Pfizer Inc.

  公开号：US20030187053A1

  公开（公告）日：2003-10-02

  The invention relates to triamide MTP/ApoB inhibitors of the formula 1 1 wherein R 1 -R 8 are as defined in the specification, as well as pharmaceutical compositions and uses thereof, and processes for preparing the compounds. The compounds of the invention are useful for the treatment of obesity and lipid disorders.

  本发明涉及三酰胺MTP/ApoB抑制剂，其化学公式为1，其中R1-R8如说明书所述，以及包含这些化合物的药物组合物及其用途，以及制备这些化合物的方法。本发明的化合物可用于治疗肥胖和脂质紊乱。
• Microsomal triglyceride transfer protein inhibitor
  申请人：Pfizer Inc

  公开号：US20040132745A1

  公开（公告）日：2004-07-08

  The present invention provides inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion having Formula (I) which are useful for the treatment of obesity and related diseases, as well as prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising the compounds of the present invention and to methods of treating obesity, atherosclerosis, and related diseases and/or conditions with the compounds of the present invention, either alone or in combination with other medicaments, including lipid-lowering agents. 1

  本发明提供了具有公式(I)的微粒体甘油三酯转运蛋白（MTP）和/或载脂蛋白B（Apo B）分泌抑制剂，用于治疗肥胖及相关疾病，以及预防和治疗动脉粥样硬化和其临床后遗症，降低血清脂质，以及预防和治疗相关疾病。本发明还涉及包含本发明化合物的药物组合物，以及使用本发明化合物单独或与其他药物（包括降脂药）联合治疗肥胖、动脉粥样硬化和相关疾病/状况的方法。
• In vitro and in vivo profile of 5-[(4′-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), a novel potent MTP inhibitor for obesity
  作者：Jin Li、Brian S. Bronk、John P. Dirlam、Alan E. Blize、Peter Bertinato、Burton H. Jaynes、Anne Hickman、Christine Miskell、Usha A. Pillai、Jay S. Tibbitts、Michelle L. Haven、Nicole L. Kolosko、Chris J. Barry、Tara B. Manion

  DOI：10.1016/j.bmcl.2007.01.018

  日期：2007.4

  The synthesis of a novel gut selective MTP inhibitor, 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrated excellent potency against MTP enzyme in HepG2 cells and canine hepatocytes. This novel MTP inhibitor also showed excellent efficacy when tested in a canine food intake model. (c) 2007 Elsevier Ltd. All rights reserved.
• Discovery of potent and orally active MTP inhibitors as potential anti-obesity agents
  作者：Jin Li、Peter Bertinato、Hengmiao Cheng、Bridget M. Cole、Brian S. Bronk、Burton H. Jaynes、Anne Hickman、Michelle L. Haven、Nicole L. Kolosko、Chris J. Barry、Tara B. Manion

  DOI：10.1016/j.bmcl.2006.02.058

  日期：2006.6

  We have successfully identified a number of novel MTP inhibitors with single digit nanomolar potency. Analogues 10aq and 10dq demonstrated in vivo efficacy in a murine gut retention assay. (c) 2006 Elsevier Ltd. All rights reserved.
• TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION
  申请人：Pfizer Products Inc.

  公开号：EP1404653B1

  公开（公告）日：2008-08-20